ClinicalTrials.gg
CompletedNCT02393950FIMPAMUpdated Dec 23, 2016Results posted

Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers

A Phase 1 interventional study of ODM-106 and Placebo in Healthy Volunteer Study, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-23.

Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The study is a dose escalation study with 8 planned dose levels. The study is a 4-period crossover design where each healthy volunteer will be randomised to receive three dose levels of ODM-106 (single doses) and one dose of placebo. The study will look at the pharmacokinetics (how the body handles the drug) and pharmacodynamics (how the drug affects the body) of ODM-106.

Read the detailed description

Eight planned dose levels of ODM-106 will be compared with placebo.There will be 2 panels of subjects with 4 dose levels in each panel. Subjects will be randomised to receive 3 dose levels of active treatment (single doses) and 1 dose of placebo. The dose levels will be escalated from the smallest dose upwards within the study and within the study subject. A third panel of 8 subjects may be included to investigate further dose levels of ODM-106, investigate the effect of taking ODM-106 with food or to compare two different formulations of ODM-106. For an individual subject, the study will consist of a screening period (maximum 4 weeks), 4 study treatment periods with a wash-out period between each study treatment administration and a post-treatment period of about 2 weeks.

The study duration for an individual will be approximately 12-16 weeks. Blood samples will be collected for the assessment of the concentration of ODM-106 and its metabolite.Plasma samples and cumulative urinary samples will be collected for metabolite screening. Safety will be assessed by a 12-lead electrocardiogram (ECG), continuous ECG monitoring, Holter ECG, supine and orthostatic blood pressure and heart rate, body temperature, physical examination, electroencephalogram (EEG), laboratory safety assessments and adverse events. Sedation and psychomotor tests and a quantitative EEG will also be performed.

02

Conditions studied

  • Healthy Volunteer Study
03

In context

Lead sponsor

Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained.
  • Participants must be able to speak, read and understand German.
  • Good general health ascertained by detailed medical history and physical examinations.
  • Males 18-45 years (inclusive).
  • (BMI) 18-30 kg/m2 inclusive
  • Weight 55-95 kg (inclusive).
  • Participants with female partners of must adhere to a proper form of from first study treatment administration until 3 months after the end-of-study visit.

Exclusion criteria

Exclusion Criteria:

  • A predictable poor compliance or inability to understand and comply with protocol requirements, instructions and protocol-stated restrictions or communicate well with the investigator.
  • Vulnerable subjects.
  • Veins unsuitable for repeated venipuncture.
  • Evidence of cardiovascular, renal, hepatic, haematological, gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator. The participants should be healthy subjects.
  • Subjects with a medical history of relevant psychiatric disorders or evidence of significant neuropsychiatric disease
  • Any condition requiring regular concomitant medication including herbal products or likely to need any concomitant medication during the study.
  • Definite or suspected personal history of to drugs or .
  • Intake of any medication that could affect the outcome of the study, as judged by the investigator, within 2 weeks before first study treatment administration (2 months for enzyme inducing drugs like rifampicin or carbamazepin), or less than 5 times the half-life of the medication.
  • A history of alcoholism or excess alcohol intake (including regular consumption of more than 21 units of alcohol per week) .
  • Use of nicotine-containing products within 6 months of admission and inability to refrain from using nicotine-containing products during the study.
  • History of drug abuse or positive drug screen for amphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, methamphetamine or methadone.
  • Propensity to get headache when refraining from caffeine-containing beverages.
  • Blood donation or loss of clinically relevant amount of blood within 2 months before the screening visit.
  • Abnormal 12-lead finding of clinical relevance at the screening visit
  • Heart rate (HR) \< 50 bpm or > 90 bpm after 10 min in rest (supine) at the screening visit
  • At the screening visit: systolic BP \< 90 mmHg or > 140 mmHg, diastolic BP \< 50 mmHg or > 90 mmHg, orthostatic hypotension decrease of greater than or equal to 20 mmHg for systolic BP, decrease of greater than or equal to 10 mmHg for diastolic BP.
  • Abnormal 24-h Holter of clinical relevance at the screening visit,
  • Positive serology to (HIV) antibodies, surface antigen (HBsAg) or virus (HCV) antibodies.
  • Any abnormal value of laboratory, vital signs, or physical examination, which may in the opinion of the investigator interfere with the interpretation of the test results or cause a health risk for the subject if he takes part in the study.
  • Participation in an drug study within 2 months before entry into this study.
  • An employee, a direct or indirect relative of the employee of the contract research organisation or the sponsor.
  • Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the subject.
  • Subject with abnormal standard EEG judged as clinically relevant by the investigator at screening.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Drug: ODM-106

    Oral capsules dosage 2-800mg once daily for one day

    Drug: ODM-106

  • Placebo comparator
    Drug: Placebo

    Oral capsules given once daily for one day

    Drug: Placebo

Interventions

  • DrugODM-106

    Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.

  • DrugPlacebo

    Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability.

    Clinically relevant changes from baseline in safety laboratory assessments (haematology, clinical chemistry, urinalysis), vital signs (pulse and heart rate), 12 lead electrocardiograms, Holter electrocardiograms, telemetry, physical examination.

    Time frame: From screening up to 16 weeks

Secondary outcomes

  1. Peak Plasma Concentration (cMax) of ODM-106

    cMax of ODM-106 after single dosing of either Capsule B or Capsule A

    Time frame: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.

  2. Area Under the Plasma Concentration Versus Time Curve (AUC) of ODM-106

    AUC of ODM-106 after single oral dosing of either Capsule B or Capsule A.

    Time frame: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine sampling, pre-dose and for 24 hours post dose at each dose level

  3. Time to Peak Plasma Concentration (Tmax) of ODM-106

    tmax of ODM-106 after single oral dosing of Capsule B or Capsule A

    Time frame: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level

  4. Elimination Half-life of ODM-106

    Elimination half-life of ODM-106 after single dosing of either Capsule B or Capsule A

    Time frame: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.

  5. Metabolite Screening in Plasma and Urine

    Metabolite screening in plasma and urine after single dosing

    Time frame: Plasma samples at pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine samples, pre-dose and for 24 hours post dose at each dose level

  6. Effect of ODM-106 on Growth Hormone Levels

    Growth hormone levels (Cmax) in serum after single oral dosing with either ODM-106 Capsule B, ODM-106 Capsule A or placebo.

    Time frame: Predose and 1, 2, 3,4, 6 and 8 hours post dose at each dose level.

  7. Sedation Scores on a Visual Analogue Scale (VAS)

    Assessment of sedation by subject

    Time frame: Pre-dose and at 1, 6 and 10.5h post dose at each dose level

  8. Dexterity and Reaction Times

    Selected battery of psychomotor tests

    Time frame: Pre-dose and at 1 and 6h post dose at each dose level

  9. Quantitative EEG

    Quantitative analysis of EEG

    Time frame: Pre-dose and at 1, 6 and 10 h post dose at each dose level

07

Results

Posted Dec 23, 2016

Participant flow

Healthy male volunteers were recruited

Participant flow — Overall Study
MilestonePanel 1Panel 2
Started99
Period 188
Period 288
Period 388
Period 488
Completed88
Not completed11
Withdrew: Adverse event10
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryNumber of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability.

Clinically relevant changes from baseline in safety laboratory assessments (haematology, clinical chemistry, urinalysis), vital signs (pulse and heart rate), 12 lead electrocardiograms, Holter electrocardiograms, telemetry, physical examination.

Time frame:
From screening up to 16 weeks
Reported as:
Number · subjects affected
Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability.
subjects affectedODM-106 Capsule B 2mgODM-106 Capsule B 10mgODM-106 Capsule B 25mgODM-106 Capsule B 50mgODM-106 Capsule B 100mg (1 x 100mg)ODM-106 Capsule B 100mg (10 x 10mg)ODM-106 Capsule B 200mgODM-106 Capsule A 100mgPlacebo
Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability.045121323
SecondaryPeak Plasma Concentration (cMax) of ODM-106

cMax of ODM-106 after single dosing of either Capsule B or Capsule A

Time frame:
Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.
Reported as:
Mean · ng/ml
Peak Plasma Concentration (cMax) of ODM-106
ng/mlODM-106 Capsule B 2mgODM-106 Capsule B 10mgODM-106 Capsule B 25mgODM-106 Capsule B 50mgODM-106 Capsule B 100mg (1 x 100mg)ODM-106 Capsule B 100mg (10 x 10mg)ODM-106 Capsule B 200mgODM-106 Capsule A 100mgPlacebo
Peak Plasma Concentration (cMax) of ODM-1069.1 ± 4.218.4 ± 11.467.8 ± 51.7119.2 ± 60.122.0 ± 20.1225.9 ± 177.2547.7 ± 319.58.3 ± 9.1—
SecondaryArea Under the Plasma Concentration Versus Time Curve (AUC) of ODM-106

AUC of ODM-106 after single oral dosing of either Capsule B or Capsule A.

Time frame:
Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine sampling, pre-dose and for 24 hours post dose at each dose level
Reported as:
Mean · h*ng/ml
Area Under the Plasma Concentration Versus Time Curve (AUC) of ODM-106
h*ng/mlODM-106 Capsule B 2mgODM-106 Capsule B 10mgODM-106 Capsule B 25mgODM-106 Capsule B 50mgODM-106 Capsule B 100mg (1 x 100mg)ODM-106 Capsule B 100mg (10 x 10mg)ODM-106 Capsule B 200mgODM-106 Capsule A 100mgPlacebo
Area Under the Plasma Concentration Versus Time Curve (AUC) of ODM-10616.9 ± 8.861.3 ± 44.1213.8 ± 78.7559.4 ± 310.9297.4 ± 346.31089.2 ± 977.02850.8 ± 2319.882.0 ± 64.7—
SecondaryTime to Peak Plasma Concentration (Tmax) of ODM-106

tmax of ODM-106 after single oral dosing of Capsule B or Capsule A

Time frame:
Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level
Reported as:
Mean · h
Time to Peak Plasma Concentration (Tmax) of ODM-106
hODM-106 Capsule B 2mgODM-106 Capsule B 10mgODM-106 Capsule B 25mgODM-106 Capsule B 50mgODM-106 Capsule B 100mg (1 x 100mg)ODM-106 Capsule B 100mg (10 x 10mg)ODM-106 Capsule B 200mgODM-106 Capsule A 100mgPlacebo
Time to Peak Plasma Concentration (Tmax) of ODM-1060.7 (0.5 to 1.0)1.9 (1.5 to 3.0)1.5 (0.5 to 3.0)2.1 (0.8 to 3.5)5.8 (1.5 to 23.9)1.5 (0.8 to 3.5)1.5 (0.8 to 3.5)3.0 (1.5 to 4.0)—
SecondaryElimination Half-life of ODM-106

Elimination half-life of ODM-106 after single dosing of either Capsule B or Capsule A

Time frame:
Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.
Reported as:
Mean · h
Elimination Half-life of ODM-106
hODM-106 Capsule B 2mgODM-106 Capsule B 10mgODM-106 Capsule B 25mgODM-106 Capsule B 50mgODM-106 Capsule B 100mg (1 x 100mg)ODM-106 Capsule B 100mg (10 x 10mg)ODM-106 Capsule B 200mgODM-106 Capsule A 100mgPlacebo
Elimination Half-life of ODM-1069.5 ± 5.520.6 ± 12.723.0 ± 2.127.3 ± 4.723.5 ± 6.327.4 ± 9.232.1 ± 10.021.7 ± 3.2—
SecondaryMetabolite Screening in Plasma and Urine

Metabolite screening in plasma and urine after single dosing

Time frame:
Plasma samples at pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine samples, pre-dose and for 24 hours post dose at each dose level

Results for this outcome have not been posted.

SecondaryEffect of ODM-106 on Growth Hormone Levels

Growth hormone levels (Cmax) in serum after single oral dosing with either ODM-106 Capsule B, ODM-106 Capsule A or placebo.

Time frame:
Predose and 1, 2, 3,4, 6 and 8 hours post dose at each dose level.
Reported as:
Geometric mean · ng/ml
Effect of ODM-106 on Growth Hormone Levels
ng/mlODM-106 Capsule B 2mgODM-106 Capsule B 10mgODM-106 Capsule B 25mgODM-106 Capsule B 50mgODM-106 Capsule B 100mg (1 x 100mg)ODM-106 Capsule B 100mg (10 x 10mg)ODM-106 Capsule B 200mgODM-106 Capsule A 100mgPlacebo
Effect of ODM-106 on Growth Hormone Levels1.7 ± 3.20.47 ± 1.041.05 ± 2.881.93 ± 1.990.8 ± 1.362.23 ± 6.120.82 ± 0.684.14 ± 4.961.01 ± 2.45
SecondarySedation Scores on a Visual Analogue Scale (VAS)

Assessment of sedation by subject

Time frame:
Pre-dose and at 1, 6 and 10.5h post dose at each dose level

Results for this outcome have not been posted.

SecondaryDexterity and Reaction Times

Selected battery of psychomotor tests

Time frame:
Pre-dose and at 1 and 6h post dose at each dose level

Results for this outcome have not been posted.

SecondaryQuantitative EEG

Quantitative analysis of EEG

Time frame:
Pre-dose and at 1, 6 and 10 h post dose at each dose level

Results for this outcome have not been posted.

Adverse events

Collected over From the start of study treatment until the end of study visit (approximately 12-16 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ODM-106 Capsule B 2mg—0/6 (0%)0/6 (0%)
ODM-106 Capsule B 10mg—0/6 (0%)4/6 (66.7%)
ODM-106 Capsule B 25mg—0/6 (0%)5/6 (83.3%)
ODM-106 Capsule B 50mg—0/6 (0%)1/6 (16.7%)
ODM-106 Capsule B 100mg (1 x 100mg)—0/6 (0%)2/6 (33.3%)
ODM-106 Capsule B 100mg (10 x 10mg)—0/6 (0%)1/6 (16.7%)
ODM-106 Capsule B 200mg—0/6 (0%)3/6 (50%)
ODM-106 Capsule A 100mg—0/6 (0%)2/6 (33.3%)
Placebo—0/16 (0%)3/16 (18.8%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventODM-106 Capsule B 2mgODM-106 Capsule B 10mgODM-106 Capsule B 25mgODM-106 Capsule B 50mgODM-106 Capsule B 100mg (1 x 100mg)ODM-106 Capsule B 100mg (10 x 10mg)ODM-106 Capsule B 200mgODM-106 Capsule A 100mgPlacebo
HEADACHENervous system disorders0/61/64/60/60/60/60/60/61/16
NASOPHARYNGITISInfections and infestations0/61/61/60/60/60/63/60/60/16
SUNBURNInjury, poisoning and procedural complications0/60/61/60/60/60/60/60/60/16
RHYTHM IDIOVENTRICULARCardiac disorders0/61/60/60/60/60/60/60/60/16
VENTRICULAR EXTRASYSTOLESCardiac disorders0/61/60/60/60/60/60/60/60/16
EPISTAXISRespiratory, thoracic and mediastinal disorders0/60/60/60/60/61/61/60/60/16
NASAL DRYNESSRespiratory, thoracic and mediastinal disorders0/60/60/60/60/61/61/60/60/16
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders0/61/60/60/61/60/60/60/60/16
PRODUCTIVE COUGHRespiratory, thoracic and mediastinal disorders0/60/60/60/60/60/60/61/60/16
DISTURBANCE IN ATTENTIONNervous system disorders0/60/61/60/60/60/60/60/60/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Panel 1Panel 2Total
<=18 years000
Between 18 and 65 years9918
>=65 years000
Gender
Gender(Participants)Panel 1Panel 2Total
Female000
Male9918
Region of Enrollment
Region of Enrollment(participants)Panel 1Panel 2Total
Germany9918
08

Study locations

1 site
  • Parexel International GmbH
    Berlin, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Oct 2015 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2015
First posted
Mar 20, 2015
Start
Mar 2015
Primary completionActual
Oct 2015
CompletionActual
Mar 2016
Results first posted
Dec 23, 2016
Last update
Dec 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02393950
Responsible party
Sponsor
First posted
Mar 20, 2015
Start date
Mar 2015
Primary completion
Oct 2015
Completion
Mar 2016
Results posted
Dec 23, 2016
Last update
Dec 23, 2016

Study contacts

Rainard Fuhr, MD
principal investigator · Parexel International GmbH, Berlin, Germany
John Whiteside
study director · Orion Corporation, Orion Pharma

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion